Inici › Càncer de pulmó › Nebraska › Omaha
Assaigs clínics de Càncer de pulmó a Omaha, NE
12 estudis de Càncer de pulmó busquen participants en centres de Omaha i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
ReclutantFase 3
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
- Nebraska Methodist Hospital, Omaha
- Nebraska Medicine-Village Pointe, Omaha
- i 3 més
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
ReclutantFase 3
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists - Methodist, Omaha
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Bergan, Omaha
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
ReclutantFase 2/3
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
ReclutantFase 2
- Research Site, Omaha
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
ReclutantFase 3
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
- Nebraska Methodist Hospital, Omaha
- Heartland Oncology and Hematology LLP, Council Bluffs · a 4 mi
- i 1 més
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
ReclutantFase 1/2
- Nebraska Cancer Specialists, Omaha
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
ReclutantFase 2
- University of Nebraska Medical Center, Omaha
Integrated Cancer Repository for Cancer Research
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Methodist Estabrook Cancer Center, Omaha
- Nebraska Methodist Health System, Omaha
- University of Nebraska Medical Center, Omaha
- i 1 més
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
ReclutantFase 2
- University of Nebraska Medical Center, Omaha
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
ReclutantFase 1/2
- Nebraska Cancer Specialists, Omaha
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Omaha
Assaigs de Càncer de pulmó en altres ciutats
- Houston, TX78 estudis
- Boston, MA62 estudis
- New York City, NY60 estudis
- Los Angeles, CA45 estudis
- Washington, DC41 estudis
- Arlington, VA41 estudis
- Chicago, IL41 estudis
- Nashville, TN40 estudis
- Baltimore, MD40 estudis
- St. Louis, MO39 estudis
- Columbus, OH37 estudis
- Philadelphia, PA36 estudis
Altres estudis a Omaha
- Càncer de pròstata27 estudis
- Càncer de pulmó de cèl·lules no petites24 estudis
- Càncer de mama22 estudis
- Càncer colorrectal18 estudis
- Càncer (tots els tipus)18 estudis
- Mieloma múltiple16 estudis
- Limfoma no Hodgkin14 estudis
- Càncer d'ovari14 estudis
- Càncer de pàncrees14 estudis
- Carcinoma de cèl·lules escamoses de cap i coll13 estudis
- Insuficiència cardíaca13 estudis
- Càncer metastàtic13 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.